A comparison of the suppression of human transferrin synthesis by lead and lipopolysaccharide.
Transferrin, as the major iron-transport protein in serum and other body fluids, has a central role in managing iron the body receives. Liver is a major site of transferrin synthesis, and in this study we present evidence that liver synthesis of human transferrin is suppressed by both the toxic metal lead and bacterial lipopolysaccharide, an inducer of the hepatic acute phase response. The responses of intact endogenous transferrin in the human hepatoma cell line HepG2 and chimeric human transferrin-chloramphenicol acetyltransferase genes in transgenic mice were examined. In HepG2 cells, 35S-transferrin protein synthesis and mRNA levels were suppressed by 100 microM and 10 microM lead acetate as early as 24 h after the initial treatment. Yet, synthesis of two proteins known to respond in the hepatic acute phase reaction, complement C3 and albumin, was not altered by the lead treatment. In transgenic mouse liver, lead suppressed expression of chimeric human transferrin genes at both the protein and mRNA levels, but LPS only suppressed at the protein level. The study indicates that lead suppresses human transferrin synthesis by a mechanism that differs from the hepatic acute phase response and that lead may also affect iron metabolism in humans by interfering with transferrin levels.
Barnum-Huckins
K M
KM
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio 78284, USA.
Martinez
A O
AO
Rivera
E V
EV
Adrian
E K
EK
Herbert
D C
DC
Weaker
F J
FJ
Walter
C A
CA
Adrian
G S
GS
D000210:Acute-Phase Reaction / Q000378:metabolism; D000418:Albumins / Q000096:biosynthesis; D000818:Animals; D006528:Carcinoma, Hepatocellular; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics; D003176:Complement C3 / Q000096:biosynthesis; D006801:Humans; D007854:Lead / Q000633:toxicity*; D008070:Lipopolysaccharides / Q000633:toxicity*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008113:Liver Neoplasms; D051379:Mice; D008822:Mice, Transgenic; D009942:Organometallic Compounds / Q000633:toxicity*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000187:drug effects; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics; D014168:Transferrin / Q000096:biosynthesis* / Q000187:drug effects / Q000235:genetics; D014407:Tumor Cells, Cultured
D000418:Albumins; D003176:Complement C3; D008070:Lipopolysaccharides; D009942:Organometallic Compounds; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D014168:Transferrin; D007854:Lead; D015500:Chloramphenicol O-Acetyltransferase; C008261:lead acetate